CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today reported recent pipeline and business highlights and second quarter 2021 financial results.
Full Story >>
Vote
+50